Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to enter for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.

Propella Therapeutics, Inc. is a private company headquartered in Pittsboro, NC. The firm develops platform that combines lymphatic targeting with medicinal chemistry. It was founded by William E. Peterson, Charles Birbara and Milt V. Peterson. William Moore is currently the CEO of the company.\nThe company says this about itself: Propella Therapeutics is a biopharmaceutical company that has developed a platform that combines medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Lymphatic targeting enables therapies to be delivered directly to therapeutic target tissues including the lymph nodes and bone, thereby enhancing efficacy and bypassing plasma compartment safety and efficacy limitations and first-pass liver effects. Propella is currently in the Phase 1 portion of a Phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The privately held development-stage company, based in Pittsboro, N.C., is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care.

Dr Rentschler GmbH & Co Medizin KG, a subsidiary of Bausch Health Cos., Inc., is a company headquartered in Germany. The firm makes cardiovascular medicines. It was acquired by Fuisz Technologies Ltd., now a subsidiary of Bausch Health Cos., Inc. from Rentschler Arzneimittel GmbH on March 12, 1998 for $19.20 million.

HEXAL is the German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. HEXAL brings biosimilars to the German market. Biosimilars are high-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to traditional, chemically synthesized medicines. In Germany HEXAL employs more then 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.

Engages in priniting activities

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.

Weifang Aotong Pharmaceutical Co., Ltd., established on 2012-11-19, Business scope includes production and sales:FBacid,CSacid,SHacid(The validity period is subject to the license);Manufacturing and Sales:gallic acid,Methyl gallate,Propyl gallate,3,4,5-trimethoxybenzoic acid,3,4,5-Methyl trimethoxybenzoate,2,4,5-Triamino-6-Hydroxypyrimidine Sulfate,2-Amino-6-Hydroxypurine,mono-p-nitrobenzyl malonate,p-nitrobenzyl alcohol,Aciclovir;Technical research on pharmaceutical and chemical products,consult;Import and export,Technology Import and Export(Except for the import and export of goods or technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Shogoo Pharmaceuticals KK provides novel pharmaceutical products. It also licenses, develops, imports, exports, markets, and distributes pharmaceutical products. It provides medicines mainly for high unmet diseases. Shogoo Pharmaceuticals was founded in 2005 and is located in Tokyo, Japan.

Novell offers antibiotics, gastrointestinal, nutrition, supplement, vitamins, and mineral medicine.

Hubei Keyi Pharmaceutical Co., Ltd. is a pharmaceutical company that engages in the research, production, and management integration of antiviral drugs. It offers drugs such as ganciclovir, ribavirin, acyclovir, penciclovir, valacyclovir & imiquimod. The company is headquartered in Hubei, China.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. The company is driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions. The overactive immune response related to activation of tissue-resident Herpes Simplex Virus-1 (HSV-1) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome (CFS), and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of the disease. Virios Therapeutics' IMC-1, is a combination of antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral-mediated disease burden. In a Phase 2a proof-of-concept trial for fibromyalgia, IMC-1 provided statistically significant improvement versus placebo in the primary endpoint of pain reduction. The company plans to enter a Phase 2b trial in the 1Q21, with topline data expected in the 1Q22. Virios Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.

NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.

Rentschler Arzneimittel GmbH, a subsidiary of MEDICE Arzneimittel P��tter GmbH & Co. KG, is a company headquartered in Laupheim, Germany, that manufactures over-the-counter drugs. MEDICE Arzneimittel P��tter GmbH & Co. KG acquired Rentschler Arzneimittel GmbH from Dr. Rentschler Holding GmbH & Co. KG on March 16, 2006.

Manufactures pharmaceutical products

Scotia Pharmaceuticals Ltd. engages in a pharmaceutical company. The company was founded on November 2, 1978 and is headquartered in London, the United Kingdom.

Oclassen Pharmaceuticals Inc, headquartered in San Rafael, CA develops and markets specialty pharmaceuticals for the prevention, diagnosis and treatment of skin diseases. Oclassen Pharmaceuticals develops and markets products for the dermatology and wound-care markets.